Neutralization of SARS-CoV-2 VOC 501Y.V2 by human antisera elicited by both inactivated BBIBP-CorV and recombinant dimeric RBD ZF2001 vaccines
Huang, B.; Dai, L.; Wang, H.; Hu, Z.; Tan, W.; Gao, G. F.; Yang, X.
Show abstract
Recently, the emerged and rapidly spreading SARS-CoV-2 variant of concern (VOC) 501Y.V2 with 10 amino acids in spike protein were found to escape host immunity induced by infection or vaccination. Global concerns have been raised for its potential to affect vaccine efficacy. Here, we evaluated the neutralization activities of two vaccines developed in China against 501Y.V2. One is licensed inactivated vaccine BBIBP-CorV and the other one is recombinant dimeric receptor-binding domain (RBD) vaccine ZF2001. Encouragingly, both vaccines largely preserved neutralizing titres, with slightly reduction, against 501Y.V2 authentic virus compare to their titres against both original SARS-CoV-2 and the currently circulating D614G virus. These data indicated that 501Y.V2 variant will not escape the immunity induced by vaccines targeting whole virus or RBD.
Matching journals
The top 7 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Humoral immunity induced by XEC monovalent vaccines against SARS-CoV-2 variants including XEC, LP.8.1, NB.1.8.1, XFG, and BA.3.2 95%
- Baculoviral COVID-19 Delta DNA vaccine cross-protects against SARS-CoV2 variants in K18-ACE2 transgenic mice 95%
- Immunological features that determine the strength of antibody responses to BNT162b2 mRNA vaccine against SARS-CoV-2 94%
Similar papers in this journal
- No more than three PlpE non-overlapping epitopes trigger significant antibody production in individuals vaccinated with the Pasteurella multocida epitope-chimeric proteins 95%
- A novel simian adenovirus vectored COVID-19 vaccine elicits effective mucosal and systemic immunity in mice by intranasal and intramuscular vaccination regimens 94%
- Functional and quantitative evaluation of BNT162b2 SARS-CoV-2 vaccine-induced immunity 94%
Similar papers in this journal
- Prime-boost vaccination of mice and Rhesus macaques with two novel adenovirus vectored COVID-19 vaccine candidates 95%
- Herpes zoster mRNA vaccine induces superior vaccine immunity over licensed vaccine in mice and rhesus macaques 94%
- A tandem-repeat dimeric RBD protein-based COVID-19 vaccine ZF2001 protects mice and nonhuman primates 94%
Similar papers in this journal
- Virus-like particles (VLPs) are efficient tools for boosting mRNA-induced antibodies 96%
- Addressing SARS-CoV-2 Evolution: Neutralization of Emerging Variants of Concern by the AVX/COVID-12 'Patria' Vaccine Based on HexaPro-S Ancestral Wuhan Spike or Its Updated BA.2.75.2 Version 96%
- Omicron booster in ancestral strain vaccinated mice augments protective immunities against both the Delta and Omicron variants 94%
Similar papers in this journal
- Neutralization of SARS-CoV-2 variants by rVSV-ΔG-spike-elicited human sera 95%
- Retention of Neutralizing response against SARS-CoV-2 Omicron variant in Sputnik V vaccinated individuals 94%
- A Newcastle disease virus (NDV) expressing membrane-anchored spike as a cost-effective inactivated SARS-CoV-2 vaccine 94%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.